High VS Low Flow Nasal O2 for Acute Hypercapnic Respiratory Failure
Acute Hypercapnic Respiratory Failure, Acute Exacerbation of COPD
About this trial
This is an interventional treatment trial for Acute Hypercapnic Respiratory Failure focused on measuring Acute exacerbation of COPD, High flow nasal oxygen, High flow nasal insufflation
Eligibility Criteria
Inclusion Criteria:
- Adult patients > 18 years of age
- Acute Hypercapnic respiratory failure with pH < 7.35 and pCO2 > 6 KPa
Exclusion Criteria:
- Age < 18 years
- Pregnant or Breast-Feeding
- Patient cannot read and understand English
- Hypercapnia secondary to a drug toxicity or non-pulmonary aetiology
- Hypercapnia secondary to exacerbation of asthma
- Contraindication to NIV
- Contraindication to HFNC
- Not for escalation to NIV
- pH < 7.15
- GCS 8 or less
- Shock defined as systolic < 90 mmHg or a reduction by 20mmHg from usual systolic BP despite volume resuscitation
- Respiratory or cardio-respiratory arrest
- Any other indication that requires immediate invasive/non-invasive mechanical ventilation
Sites / Locations
- Mater HospitalRecruiting
- Royal Victoria HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
High flow nasal therapy (HFNT)
Low flow oxygen (LFO)
Characterized by an elevated arterial CO2 (PaCO2) level of > 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
Characterized by an elevated arterial CO2 (PaCO2) level of > 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.